Atovaquone-d₅  (Synonyms: Atavaquone-d₅)

Atovaquone-d₅ is the deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and  P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

371.87

C₂₂H₁₄D₅ClO₃

1329792-63-3

95233-18-4

O=C1C([C@@]2([2H])C([2H])([2H])C[C@H](C3=CC=C(C=C3)Cl)CC2([2H])[2H])=C(C(C4=CC=CC=C41)=O)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief]

  [2]. Nilsen A, et al. Quinolone-3-diarylethers: a new class of antimalarial drug.Sci Transl Med. 2013 Mar 20;5(177):177ra37.  [Content Brief]

  [3]. Schöler N, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.Antimicrob Agents Chemother. 2001 Jun;45(6):1771-9.  [Content Brief]